Off-label use of rhBMP-2 as bone regeneration strategies in mandibular ameloblastoma unicystic

Abstract

Jawbone reconstruction after tumor resection is one of the most challenging clinical tasks for maxillofacial surgeons. Osteogenic, osteoinductive, osteoconductive and non-antigenic properties of autogenous bone place this bone as the gold standard for solving problems of bone availability. However, the need for a second surgical site to harvest the bone graft increases significantly both the cost and the morbidity associated with the reconstructive procedures. Bone grafting gained an important tool with the discovery of bone morphogenetic proteins in 1960. Benefit of obtaining functional and real bone matrix without need of second surgical site seems to be the great advantage of use bone morphogenetic proteins. This study analyzed the use of rhBMP-2 in unicystic ameloblastoma of the mandible, detailing its structure, mechanisms of cell signaling and biological efficacy, in addition to present possible advantages and disadvantages of clinical use of rhBMP-2 as bone regeneration strategy.

Collagen particles with collagen-binding bone morphogenetic protein-2 promote vertebral laminar regeneration in infant rabbits

“…Recombinant human BMPs (rhB-MPs) reportedly possess the osteoinductive ability to enhance fracture healing, and have been approved for clinical use by the US Food and Drug Administration [20][21][22]. The off-label use of rhBMPs in adults has been demonstrated to assist in fracture healing [23][24][25], however, rhBMPs have rarely been applied in children and adolescents. In addition, the application of rhBMP has been limited by its supraphysiological dosage, adverse clinical outcomes, and expense [25,26].…”